Figure 1
Comparison of peripheral blood: (A) lymphocytes (low SSC and high CD45 expressing cells) after SAH during EBI and DBI phases with healthy controls; (B) CD4+ T cells (expressed as %age of CD45 + leukocytes) after SAH during EBI and DBI phases with healthy controls; (C) CD4+ T cells (expressed as %age of lymphocytes) after SAH during EBI and DBI phases with healthy controls; (D) Tregs (CD25hi CD127lo, expressed as %age of CD3+ CD4+ T cells) after SAH during EBI and DBI phases with healthy controls; (E) HLA-DR− CD38− Th2 cells (expressed as %age of CD3+ CD4+ T cells) after SAH during EBI and DBI phases with healthy controls; (F) HLA-DR− CD38+ Tregs (expressed as %age of CD3+ CD4+ T cells) after SAH during EBI and DBI phases with healthy controls; (G) HLA-DR+ CD38+ Tregs (expressed as %age of CD3+ CD4+ T cells) after SAH compared to healthy controls during EBI and DBI phases, (H) HLA-DR− CD38− Tregs (expressed as %age of CD3+ CD4+ T cells) after SAH during EBI and DBI phases compared to healthy controls. One way ANOVA followed by Tukey’s multiple comparisons test for normally distributed data. Kruskal Wallis test followed by Dunn’s multiple comparisons test for non-normally distributed data; A p value < 0.05 was considered as a significant difference. *Indicates a p value < 0.05, **indicates a p value < 0.01, ***indicates a p value < 0.001. HC healthy controls (n = 10), EBI early brain injury phase after SAH covering days 1–3 (n = 15), DBI delayed brain injury phase after SAH covering days 7–9 (n = 15).
